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Abstract
Background: Intermittent Preventive Treatment of malaria in infants using sulfadoxine-pyrimethamine (SP-IPTi) is
recommended by WHO for implementation in settings where resistance to SP is not high. Here we examine the relationship
between the protective efficacy of SP-IPTi and measures of SP resistance.
Methods and Results: We analysed the relationship between protective efficacy reported in the 7 SP-IPTi trials and
contemporaneous data from 6 in vivo efficacy studies using SP and 7 molecular studies reporting frequency of dhfr triple
and dhps double mutations within 50km of the trial sites. We found a borderline significant association between frequency
of the dhfr triple mutation and protective efficacy to 12 months of age of SP-IPTi. This association is significantly biased due
to differences between studies, namely number of doses of SP given and follow up times. However, fitting a simple
probabilistic model to determine the relationship between the frequency of the dhfr triple, dhps double and dhfr/dhps
quintuple mutations associated with resistance to SP and protective efficacy, we found a significant inverse relationship
between the dhfr triple mutation frequency alone and the dhfr/dhps quintuple mutations and efficacy at 35 days post the 9
month dose and up to 12 months of age respectively.
Conclusions: A significant relationship was found between the frequency of the dhfr triple mutation and SP-IPTi protective
efficacy at 35 days post the 9 month dose. An association between the protective efficacy to 12 months of age and dhfr
triple and dhfr/dhps quintuple mutations was found but should be viewed with caution due to bias. It was not possible to
define a more definite relationship based on the data available from these trials.
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Introduction
Intermittent preventive treatment of malaria with sulfadoxine-
pyrimethamine (SP) in infants (SP- IPTi) reduced the incidence of
clinical malaria in areas of sub-Saharan Africa with low to
moderate SP resistance in sub-Saharan Africa [1–5] but had no
significant protective effect in one area of high SP resistance [6]
and one area of low transmission [7]. Based on the findings from
these 7 randomised trials, a technical Expert Group convened by
the World Health Organization (WHO) in 2009 recommended
SP-IPTi for use as a malaria control tool in sub-Saharan Africa
under certain conditions [8]. Firstly, it was recommended that
IPTi programmes be implemented only in areas with moderate to
high transmission (Annual Entomological Inoculation Rates (EIR)
greater than 10 infectious bites per person per year). Second, it was
recommended that programmes are not implemented in areas
where the degree of parasite resistance to SP is high. At that time
the relationship between the level of SP resistance and the likely
efficacy of SP-IPTi at any individual site was not well defined. The
aim of this study was to explore the relationship between
protective efficacy of SP-IPTi and measures of resistance to SP
in order to better define this relationship.
The most common method for estimating SP resistance is
measurement of the in vivo efficacy of SP in the treatment of
children between the ages of 6 and 59 months with uncomplicated
malaria using WHO standard methodology [9]. Over the past 10
years, the recommended follow-up time in these studies has
changed from 14 days to 42 days and in some cases to 63 days, to
account for late treatment failures and to demonstrate the
prophylactic effect of antimalarials. Since the WHO recommends
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treatment of uncomplicated malaria with an artimisinin-based
combination therapy (ACT), it is no longer acceptable in most
countries to carry out in vivo efficacy studies of SP used alone for
treatment of uncomplicated malaria in children.
In vitro methods for measuring antimalarial drug resistance are
being proposed to enable investigation of parasite resistance to the
individual components of ACTs [10] and will be a useful adjunct
to in vivo studies. However, these methods are only available in a
few centres and no data are available from the sites of the SP-IPTi
studies.
If in vivo studies cannot ethically be carried out and in vitro assays
are unavailable then assessment of the level of resistance must rely
on studies of the frequency of molecular markers of SP resistance.
The mechanism of action of SP is well documented and point
mutations at codons 16, 50, 51, 59, 108 and 164 in the dhfr gene
[11,12] confer resistance to pyrimethamine while mutations at
codons 436, 437, 540, 581 and 613 of the dhps gene [13,14] confer
resistance to sulfadoxine. There is a non-linear relationship
between the number of mutations and resistance. However, the
presence of three dhfr mutations (dhfr triple: N51I, C59R, S108N)
and two dhps mutations (dhps double: A437G, K540E) in
Plasmodium falciparum parasites studied prior to treatment is a
significant predictor of SP treatment failure [15,16,17]. A recent
meta analysis of SP in vivo studies and mutations showed a
significant increase in the risk of therapeutic failure associated with
the dhfr triple mutation (Day 28 OR 3.1 95% CI: 2.0–4.9) and with
the dhfr-dhps quintuple mutation (Day 28 OR 5.2 95% CI 3.2–8.8)
[18].
In this paper we characterise the relationship between
protective efficacy of SP- IPTi, molecular markers of SP resistance
and estimates of SP resistance measured by in vivo efficacy studies.
By combining data from 7 randomised trials which evaluated the
efficacy of IPTi against clinical malaria with contemporaneous
data on resistance and the frequency of mutations in the dhfr and
dhps genes in the study areas, we provide estimates of SP-IPTi
protective efficacy at different levels of SP resistance with the aim
of providing evidence towards defining the level of resistance at
which SP-IPTi no longer provides a clinical protective effect.
Methods
a) Data Sources
Randomised placebo controlled (RCT) trials of IPTi were
identified by literature search using the strategy shown in
supplement file S1. Trials were only selected if they were RCT s,
all participants were infants (children,1 year old) and SP treatment
doses were given at the time of vaccination. Seven SP-IPTi trials
were identified, all were undertaken in Sub-Saharan Africa between
1999 and 2008. The dates, locations and dosing strategies of these 7
studies are summarized in Table 1. There was substantial variability
in the study design of the 7 trials, 3 out of 7 giving doses at 3, 9 and
15 months of age [2,4,7], 2 giving doses at 2,3 and 9 months of age
[5,6] and 2 giving doses at 3,4 and 9 months of age [1,3] with one of
these giving a further dose at 12 months [1]. The number of
treatments with SP-IPTi given will affect protective efficacy up to 12
months of age. Thus, whilst these data are of clinical importance,
comparisons of 12 month efficacy between trials should be viewed
with caution. Although 12 month data are shown we attach more
weight to the relationships between the protective efficacy in the 35
day post dose prophylactic period following administration of the 3
and 9month doses of SP-IPTi which were given in all trials. Because
only summary data were available, it was not possible to adjust our
estimates to properly account for variations in the exact age at the
time of administration of these doses or other factors such as ITN
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coverage between the studies. Summary data were supplied by the
Statistical Working Group of the IPTi consortium (www.IPTi-
malaria.org summarised in [19] ) and from a recently published
IPTi study [6]. Unadjusted protective efficacies (PE) were estimated
using the equation PE=12(incidence in the intervention group/
incidence in the placebo group) and are shown in Table 2.
Study sites varied in transmission intensity, the lowest being in
Gabon [7] with an incidence of 0.22 cases of malaria per person
year at risk (PYAR) and the highest being Kumasi in Ghana [2] with
an incidence of 1.29 cases PYAR. Patterns of transmission also
varied between sites with 2 sites supporting perennial transmission
[2,5], 4 sites perennial with seasonal peaks [3–7] and one site with
highly seasonal transmission [1]. ITN coverage also varied between
sites (5 studies ,30% coverage [1–4,7], and 2 sites .60% [5,6]).
A literature review was undertaken to identify data for standard
in vivo efficacy studies of SP in children under the age of 5 years
and studies of mutations in dhfr and dhps genes conducted in
locations near to the above trials in time and place. Search terms
used in the review are shown in supplement file S1. Where no
publications were found, researchers in areas where SP-IPTi had
been conducted were contacted to acquire unpublished data. In
vivo efficacy and mutation data were included if they were sampled
within 2 years from the time of the SP-IPTi study and within a
50km radius. Variables extracted were study site, estimated
distance from IPTi study site, year of study, study design, number
of participants, day 14 and/or day 28 Adequate Clinical and
Parasitological Response (ACPR) where available and frequency
of mutations in dhps and dhfr genes (see tables 1 and 2).
b) Statistical Methods
Univariate exploratory analyses of the relationship between the
protective efficacy as measured in the trials and the measure of
resistance (day 14 ACPR, frequency of triple dhfr mutation,
frequency of dhps double mutation and their combination in a
quintuple mutation) were first undertaken using non-parametric
methods (Spearman’s rank correlation) using Stata v10.1. However,
these only assess the crude relationship between summary measures,
and they will tend to under-estimate the strength of the association
when the outcome measures have not been estimated precisely. In
addition, they cannot easily be extended to predict protective
efficacy at sites with different resistance profiles. To do this, we
developed a simple non-linear probabilistic model of the relation-
ship between mutation frequencies in the dhfr and dhps genes and the
protective efficacy of SP-IPTi. The details of the development of the
model are shown in supplement file S2. Briefly, the model takes into
account the effect of each combination of mutations on PE, i.e. the
effect of wild type parasites, the effect of the mutant haplotypes in
the dhfr and dhps genes independently and when they are combined
in the quintuple genotype.
To calculate the length of protection of SP-IPTi we used the two
full data sets available (Navrongo, Ghana and Korogwe,
Tanzania) [1,6]. We examined the relationship between duration
of protection after a dose of SP-IPTi and markers of SP resistance.
The methodology used has been previously published [20,21]. In
short, person-time at risk after a particular dose of IPTi was
divided into strata to allow calculation of protective efficacy in
discrete time periods after IPTi. Random-effects Poisson regres-
sion was used to calculate protective efficacy in each time stratum.
In this analysis we use a shorter time period (21 days vs 28 days) in
order to demonstrate differences in the period of prophylaxis.
Results
Six studies measuring in vivo efficacy of SP in children under the
age of 5 years were found which met the inclusion criteria
(Table 1). One site, Kumasi in Ghana, had no contemporaneous
data on SP efficacy. ACPR was reported for the day 14 endpoint
in all 6 studies and for day 28 in 4 of the 6 studies. Molecular PCR
correction for re-infection and recrudescence was carried out in 3
of the 6 studies (Table 1).
Seven studies which met the inclusion criteria and tested for dhfr
and dhps mutations were found (Table 1). All seven studies were
undertaken within 50km of the IPTi studies and 5 of the 7 took
place at the same site. Two were community cross sectional
studies, 1 was from a study of clinical cases in an IPTi study and 4
were obtained at enrolment into standard in vivo efficacy studies.
All studies reported results on the following codons; dhfr codons 51,
59 and 108 and for dhps codons 436, 437 and 540, and these were
therefore used for further analyses. Six studies reported on
Table 2. Protective efficacy of IPTi with SP, in vivo efficacy of SP in under 5 year olds and frequency of genetic markers of SP
resistance at the seven study sites.
IPTi efficacy (95% CI) In vivo efficacy Frequency of mutations
Trial Site
35 day post dose
prophylactic effect
after 3 month dose, %
35 day post dose
prophylactic effect
after 9 month dose, %
Up to 12
months of
age, %
Day 14
ACPR, %
Day 28
ACPR, %
DHFR
triple, %
DHPS
double, %
Quintuple,
%
Ifakara, Tanzania [5] 77.8 (20, 100)* 91.1 (74, 100) 57.5 (43, 69) 68.9 59.8 24.4 8.2 3.6
Manhica,
Mozambique [3]
57.5 (22, 80) 65.2 (39, 83) 15.4 (2, 27) 78.6 Not
reported
81 56 52.9
Navrongo, Ghana [1] 75.8 (56, 89) 79.0 (70, 86) 30.0 (22, 37) 77.6 Not
reported
44 1 0
Lambare´ne´, Gabon [7] 74.8 (251, 100)** 71.5 (225, 100)**** 22.5 (217, 50) 79 46 98 4 4
Kumasi, Ghana [2] 82.0 (66, 94) 47.6 (19, 68) 20.7 (8, 31) 61 1 1.3
Tamale, Ghana [4] 65.7 (19, 91) 83.4 (66, 95) 32.1 (20, 42) 86 72.2 47 1 0.8
Korogwe, Tanzania [6] 1*** (2397, 100) 69.6 (15, 95) 210.2 (252, 20) 38.8 17.7 96.4 90 89.2
*9 cases in placebo group,
**4 cases in placebo group,
***3 cases in placebo group,
****7 cases in placebo group.
doi:10.1371/journal.pone.0012618.t002
IPTi and Drug Resistance
PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12618
mutations at codon 164 on the dhfr gene (none found mutations at
this codon) and 4 studies reported on mutations at codons 581 and
613 on the dhps gene.
Table 2 summarises the three measures of protective efficacy of
IPTi (namely the 35 day post dose prophylaxis effect of the 3 and 9
month doses of SP and the protective efficacy of SP IPTi to 12
months of age) for the seven trials, and the 14 and 28 day ACPR
and frequency of dhfr triple and dhps double mutations found in
studies conducted nearby in time and location.
Univariate associations between markers of resistance
and protective efficacy of SP-IPTi
Figure 1 shows the relationship between four measures of SP
resistance and the protective efficacy of SP-IPTi against incidence
of malaria during the 35 days after administration of the 3 and 9
months doses of SP-IPTi and up to 12 months of age. The
measures of SP resistance are: a) the day 14 failure rate from in vivo
efficacy studies; b) the frequency of the dhfr triple mutation; c) the
frequency of the dhps double mutation; and d) the frequency of the
quintuple dhfr/dhps mutation. There is some indication that as
resistance increases protective efficacy declines, as indicated by the
negative rank correlations in all comparisons and there is a
significant negative rank correlation between frequency of the
triple dhfr genotype and 12 month protective efficacy 20.75
(p = 0.05). It should be noted that the 12 month protective
efficacies are not directly comparable between trials due to
differences in both the timing and number of doses of IPTi
delivered as well as the length of follow-up.
Estimates of the relationship between mutation
frequency and protective efficacy
Figure 2 shows the fit of the model expressing the relationship
between mutation frequency and protective efficacy in each of the 7
sites for the 35 days after the 3- and 9-month doses and up to 12
months of age. For all outcomes there is close agreement between
the model and the data to which it is fitted, demonstrating that there
Figure 1. Relationship between protective efficacies of IPTi for the seven trial sites plotted against markers of resistance. (a) the 14
day ACPR (rank correlation = 0.03 (p = 0.96) for the 3 month dose, 0.09 (p = 0.87) for the 9 month dose and 0.26 (p = 0.62) over 12 months); (b) the
frequency of the dhfr triple mutation (rank correlation=20.54 (p = 0.22) for the 3 month dose, 20.61 (p = 0.15) for the 9 month dose and 20.75
(p = 0.05) over 12 months); (c) the frequency of dhps double mutation (rank correlation=20.46 (p = 0.29) for the 3 month dose, 20.32 (p = 0.48) for
the 9 month dose and 20.61 (p = 0.15) over 12 months); (d) the frequency of the dhfr/dhps quintuple (rank correlation =20.66 (p = 0.16) for the 3
month dose, 20.26 (p = 0.62) for the 9 month dose and 20.71 (p = 0.11) over 12 months).
doi:10.1371/journal.pone.0012618.g001
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is a strong relationship between protective efficacy and the
frequency of resistance mutations in the population. For the 3
month dose, the model-predicted efficacy is somewhat higher than
that observed in Korgowe, although the confidence interval for the
data estimate is wide and the observed protective efficacy is within
the 95% credible interval predicted by the model. There is greater
discrepancy for the 9 month estimates with higher observed
protective efficacies in Ifakara , Lambare´ne´ and Tamale compared
to those predicted by the model and lower observed PE in Kumasi
than predicted by the model. For the 12 month outcome the model
predictions for the Ifakara and Lambare´ne´ datasets are substantially
lower than that observed whereas the model predicted a higher
efficacy for the Korogwe site. Thus, for the 9 month dose and up to
12 months of age data it appears that factors other than the
mutations investigated were influencing protective efficacy. This has
been explored in two modelling exercises [22,23].
Table 3 shows the estimated protective efficacy for 35 days
following the 3 and 9 month doses and up to 12 months of age for
wild type (no mutations) and each of the three mutation
combinations. The estimates for the dhps double mutation alone
are uncertain (as demonstrated by the wide credible intervals) since
almost all samples which contained the double mutation also
contained the triple dhfr mutation. However, because the
frequency of the double dhps mutation alone is low, this
uncertainty has little impact on the predicted efficacies for each
site. Our parameter estimates suggest that IPTi will be significantly
less efficacious in a population with 100% prevalence of the triple
dhfr mutation than in one where there are no mutations, with the
difference between the protective efficacy in the latter and former
cases estimated as20.08 (95% credible interval (CrI):20.53, 0.45)
after the 3 month dose, 0.42 (95% CrI: 0.03, 0.65) following the
Figure 2. Observed and fitted protective efficacies of IPTi for the seven trial sites. a) during 35 days after a dose at 3 months; b) during 35
days aftera dose at 9 months; and c) up to 12 months of age. Model predictions are based only on the frequency of the dhfr triple mutation, dhps
double mutation and combined dhfr and dhps quintuple mutation and do not adjust for any other differences between the trials or the trial sites.
doi:10.1371/journal.pone.0012618.g002
Table 3. Estimated protective efficacy against malaria for 35
days post 3 and 9 month dose (posterior median and 95%
credible interval) and up to 12 months of age of SP IPTi when
the parasite population has no resistance mutations, all carry
the dhfr triple mutation, all carry the dhps double mutation or
all carry the quintuple mutation (both the dhfr triple and dhps
double mutations).
Mutations
present
Estimated
PE (%) 95% CrI
After dose at 3 months None 73.0 41.8 97.4
Just dhfr triple 80.5 48.2 98.6
Just dhps
double
38.0 241.0 97.1
Both 31.8 222.5 73.5
After dose at 9 months None 94.2 74.8 99.8
Just dhfr triple 52.6 32.5 74.0
Just dhps
double
50.1 234.4 97.9
Both 67.8 30.1 91.5
Up to 12 months of age None 60.0 34.3 87.8
Just dhfr triple 0.1 226.3 25.5
Just dhps double 67.5 219.4 98.7
Both 1.8 220.6 23.4
doi:10.1371/journal.pone.0012618.t003
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dose at 9 months and 0.60 (95% CrI 0.11, 1.12) up to 12 months
of age. It was not possible from these data to provide sensible
estimates of the relative efficacy with the double mutation
compared to either no mutations, or to the triple mutation, or
with the quintuple mutation compared to the triple alone, because
of a lack of power and hence precision.
Figures 3, 4 and 5 show the expected 35 day protective efficacy
of doses of SP-IPTi given at 3 and 9 months of age and up to 12
months of age respectively for different levels of frequency of both
dhfr triple and dhps double mutations. There is little observable
relationship between protective efficacy and the frequency of the
dhfr triple mutation following the 3 month dose regardless of the
frequency of the dhps double mutations (Figure 3), most likely due
to a lack of power given the small number of events in this period.
However, there is a significant decrease in protective efficacy after
the 9 month dose with increasing frequency of the dhfr triple
mutation at low frequencies of the dhps double mutation (Figure 4
a and b, 0% and 10% frequency respectively). For higher
frequencies in the double dhps mutation, the relationship between
the dhfr triple frequency and protective efficacy is less apparent
(Figure 4 c–e). However, this is most likely due to the imprecision
of these estimates (as shown by the wider credible intervals) as in
Figure 3. Expected protective efficacy of SP- IPTi of the 3 month dose at different frequencies of the dhfr triple mutation in settings
of different frequencies of the dhps double mutation. (a) 0%, (b) 10%, (c) 50%, (d) 90% and (e) 100% frequency of the dhps double mutation.
doi:10.1371/journal.pone.0012618.g003
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practice the dhps double mutation is almost always accompanied
by a high frequency in the dhfr triple mutation. The predicted
protective efficacy up to 12 months shows a decrease for all
frequencies of the dhps double mutation (Figure 5), although again
the relationship is uncertain for higher dhps double frequencies,
and as noted the relationship for the 12 month outcome may be
biased due to variations in study design.
Results of length of protection analysis
In Navrongo Ghana, where P. falciparum resistance to SP is low,
the period of protection post IPTi dose extended to 42 days. In
contrast, in the high resistance setting of Korogwe, Tanzania, the
period of protection was reduced to 21 days with an increased risk
of malaria, shown by a non-significant negative protective efficacy
during the second 21 day period (Figure 6 a and b).
Discussion
Our results suggest that there is a reduction in the protective
efficacy of SP-IPTi with increasing molecular markers of SP
resistance in contrast to our previous analysis with fewer studies
that demonstrated no association between day 14 ACPR and
Figure 4. Expected protective efficacy of SP- IPTi after the 9month dose at different frequencies of the dhfr triple mutation in settings
of different frequencies of the dhps double mutation. (a) 0%, (b) 10%, (c) 50%, (d) 90% and (e) 100% frequency of the dhps double mutation.
doi:10.1371/journal.pone.0012618.g004
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resistance [24]. We previously stated that the site with the highest
protective efficacy for SP-IPTi, Ifakara, also had the highest
resistance using ACPR as a measure of resistance [25]. This in vivo
study was carried out immediately prior to the IPTi study in the
same study site but did not collect molecular data. In our search
for data on molecular markers of resistance we found a study that
took place around the same time and was within 20km of the IPTi
study site. The results from this study show that the Ifakara site
had the lowest frequency of dhfr and dhps mutations. Explaining
these contrasting observations is difficult. One possibility is that the
IPTi and in vivo study were located in a semi-urban site which had
a higher density of drug shops than in the rural villages where the
molecular studies were done and easier access to the district
hospital thus resulting in greater drug pressure and higher
resistance levels as reflected by the high ACPR. Another possibility
is that the high failure rate seen in the in vivo study [25] was due to
re-infections. However, this is unlikely because the incidence rate
reported in the IPTi study was low-moderate (0.36 episodes
PYAR) [5] and, if the parasites were very sensitive as found with
the molecular data, then we would expect SP to have offered
prophylaxis beyond 28 days. Hence, it is unclear which data best
represent resistance levels for the Ifakara site.
Figure 5. Expected protective efficacy of SP- IPTi up to 12months of age at different frequencies of the dhfr triplemutation in settings
of different frequencies of the dhps double mutation. (a) 0%, (b) 10%, (c) 50%, (d) 90% and (e) 100% frequency of the dhps double mutation.
doi:10.1371/journal.pone.0012618.g005
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We were able to only show a single, borderline statistically
significant association between the measures of resistance to SP
that we examined and protective efficacy of SP-IPTi using simple
exploratory analyses with the few data points available. However,
by fitting a simple probabilistic model of both dhfr triple and dhps
double mutations, which better represents the underlying
relationship between the mutations and protective efficacy, we
were able to obtain a reasonable fit to the data and thus
demonstrate a strong relationship between the level of resistance
mutations (notably dhfr triple mutation) and protective efficacy. For
low levels of the dhps double mutation, there was a significant
decrease in the efficacy of IPTi 35 days post the 9 month dose with
increasing frequency of the dhfr triple mutation. However, as the
frequency of the dhps double mutants increased the estimates of the
relationship between dhfr triple and protective efficacy became less
precise. This supports the biological plausibility of the model as
dhfr mutations first appear followed by dhps mutations. Once the
frequency of the dhfr/dhps quintuple mutation rises, selection for
more resistant haplotypes takes place, as in the case of Korogwe,
where the quintuple mutation reached saturation and there was a
high frequency of a sixth mutation, the dhps 581G mutation [26].
The analysis was limited by the scarcity of data points. In 3 of
the 7 studies there were fewer than 10 cases of malaria in the
placebo group during the 35-day period following the 3-month
dose and 1 of the 7 studies had simiarly few cases after the 9 month
dose. There was also a lack of variation in the frequency of
molecular mutations with only 2 sites having frequencies of the
dhfr/dhps quintuple mutation above 4%, and all sites with a high
frequency of the dhps double mutation also had a high frequency of
the dhfr triple mutation. Because of this, the model is unable to
provide sensible predictions of the protective efficacy for the
quintuple mutation, with the central estimate obtained being
higher than that for the dhfr triple and dhps double individually at
the 9 month dose. This is not consistent with our biological
understanding of the mechanism of resistance to SP or evidence
from in vivo studies [18] but simply reflects a lack of data rather
than an underlying problem with the model. This lack of data
meant that we were unable to undertake analyses of individual
mutations including analysis of additional mutations to the
quintuple, for example the dhps 581 G mutation found in more
than 50% of samples at the Korogwe site [26] that might make
parasites even more resistant to SP than those carrying the
quintuple mutation alone.
The use of the 12 month efficacy results for comparing sites
should be interpreted with caution as 3 out of the 7 studies gave
two treatments with SP during the first year of life whereas the
Figure 6. Length of protection of SP- IPTi in 2 settings. a) low resistance to SP and b) high resistance.
doi:10.1371/journal.pone.0012618.g006
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remaining 4 gave three doses. In addition, 4 of the 7 studies
provided 10 months of observation in the first year and 3 had only
9 months. Both these factors would have affected the protective
efficacy of SP-IPTi resulting in biased estimates of the association
between protective efficacy and resistance-conferring mutations.
The results using the 12 month endpoint show an apparent
association between protective efficacy and both the dhfr triple and
the dhfr/dhps quintuple mutations, and although this is biologically
plausible, this association suffers from bias. Thus, in an attempt to
compare like with like we chose to examine the post treatment
prophylactic periods. Whilst the 35-day post-dose protective
efficacy is meaningful in terms of comparing SP efficacy between
settings with different levels of resistance, for clinical practice a
longer period is more relevant. Unfortunately it is not straightfor-
ward to translate an expected protective efficacy at day 35 post 3
and 9 month dose predicted by the model at different frequencies
of mutations to an equivalent 12 month protective efficacy. For
example, in Korogwe, Tanzania the 35 day protective efficacy
after the 9 month dose was 70% but protective efficacy up to 12
months of age was 26% [6]. Thus further studies or modelling are
required to assess the relationship between the dhfr mutation
frequencies and protective efficacy over this longer period.
Our analysis of the length of the period of prophylaxis in the low
and high resistance settings of Navrongo, Ghana and Korogwe,
Tanzania respectively provide further insight into the mechanism
underlying the relationship between mutation frequency and
protective efficacy. In this analysis, we have shown that increasing
SP resistance shortens the period of prophylaxis. This is explained
biologically by parasites with mutations requiring greater mini-
mum inhibitory concentrations of SP to kill or suppress the
parasites [27]. Thus, SP can be efficacious while levels of SP
remain high in blood, evident from the high protective efficacy
(.55%) during 35 days after the 3 and 9 month doses in 6 out of
the 7 trial settings including those with high resistance to SP [3,6].
Observation of the length of prophylaxis in 4 of the 7 studies shows
there is a high level of protection in the 2–6 weeks after a dose of
SP-IPTi with protection declining as drug levels decrease in
settings of low resistance [20,28] and to a negative protective
efficacy in the very high resistance setting [21].
Is there a measure of SP resistance that we can use to determine
SP efficacy for IPTi? Our study suggests that an in vivo study in
asymptomatic infants specifically designed to look at the
prophylactic effect of antimalarials might be more informative if
it looked at the duration of the post dose prophylactic effect rather
than at the protective efficacy to a certain time point, such as 35
days post dose used in this analysis. If in vivo studies cannot be done
then an assessment of molecular markers should be made. Maps of
the occurrence of the key dhfr and dhps mutations across Africa
have recently been published [26,29,30] (also see www.drugresis-
tancemaps.org). These show that the highest rates of mutations of
dhfr and dhps genes are in East and Southern Africa where SP use
has been the highest. Thus, on the basis of our model we would
predict that that IPTi with SP would currently be more effective in
West and Central Africa than in East and Southern Africa where
both dhfr and dhps mutations are more frequent. However, future
expansion or contraction of SP resistance may alter this situation
and thus continued monitoring of drug resistance in malaria
endemic countries is essential. Where the frequency of the
quintuple mutation rises above 60% further resistant haplotypes
such as the dhfr 164 L in Uganda and Rwanda [30,31] and the
dhps 581 G in Tanzania, Uganda and Rwanda [26,30,31,32] are
selected. It is highly unlikely that SP- IPTi will have a significant
protective effect in areas in which these mutations are common, as
demonstrated in northern Tanzania [6]. Thus, additional
measurement of the frequency or prevalence of the quintuple
mutation alongside measurements of both the dhfr and dhps
mutations may guide policy makers in deciding where to
implement SP-IPTi. More recently, an additional Technical
Expert Group was convened by the WHO that reviewed data
on SP-IPTi protective efficacy and SP resistance that included
data from this paper. At this meeting a consensus was reached that
the cut-off for implementation for SP-IPTi should be a prevalence
of the quintuple dhfr/dhps mutation of 50%. As it is not always
possible to measure all mutations the recommendation was to use
the P falciparum dhps 540 mutation as a marker for the quintuple
mutation and where this was greater than 50% SP-IPTi should not
be implemented. In addition, the final WHO policy document
states that in situations where a National-scale implementation
may not be feasible due to varying levels of the dhps 540 mutation,
IPTi may be implemented at a Provincial or District scale,
targeting areas with dhps 540 mutation prevalence #50% [33].
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